Eli Lilly are to acquire CoLucid Pharmaceuticals for $960 million

By Catherine Rowell

Following on from the departure of John Lechleiter, President & CEO of global drug manufacturer and healthcare leader Eli Lilly and subsequent appointment of David Ricks, Senior Vice President, it has been recently announced that global drug manufacturer and healthcare leader Eli Lilly will acquire CoLucid in a new $960 million acquisition, or $46.50 per share.

CoLucid’s focus on supporting patients who suffer from migraines and subsequent trial of lasmiditan in clinical tests is scheduled to complete in 2017, with two trials recently completing.

If the trials are proved successful, treatment could be launched in the US in 2018 and would be welcomed by over 30 million individuals who suffer from migraines. Eli Lilly will also acquire other treatments CoLucid has been developing, such as the headache drug galcanezumab.

Interestingly, the breakthrough for lasmiditan originated at Eli Lilly, at which Thomas P. Mather, CoLucid's CEO stated, "We are proud of the work that CoLucid has done to develop lasmiditan, and we believe Lilly's expertise in pain and commitment to innovation are a natural fit to potentially bring this medicine to patients."

This investment firmly places Eli Lilly on the pharmaceutical map and cements their status within the industry.

Follow @BizReviewUSA and @NellWalkerMG

Read the January issue of Business Review USA & Canada here


Featured Articles

Broadridge study reveals huge impact of AI on C-suite

Broadridge Financial Solutions spoke to 500 C-suite executives from across the globe, many of whom said AI was significantly changing the way they work

PwC's Kathryn Kaminsky – the role of boards on social issues

As Vice Chair Trust Solutions Co-Leader at PwC, Kathryn Kaminsky says boards play an important role in helping businesses take action on social issues

Why your business needs a Chief Transformation Officer

Responsible for driving growth and change, the Chief Transformation Officer is the latest addition to the C-suite as business undergoes major change

12 top AI and ML trends for the enterprise in 2023 – Dataiku

Technology & AI

From NYC to Hong Kong, the rise of the private members' club

Leadership & Strategy

Meet the CEO: Jill Stelfox of Panzura, exclusive interview

Leadership & Strategy